Mark G. Kris

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

William Pao, Vincent A. Miller, Maureen F. Zakowski et al. · Proceedings of the National Academy of Sciences · 2004 · 4.3K citations · Full text

Medicine, Molecular Genetics, Oncology +16

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

William Pao, Vincent A. Miller, Katerina Politi et al. · PLoS Medicine · 2005 · 3.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial

Ethan Basch, Allison M. Deal, Mark G. Kris et al. · Journal of Clinical Oncology · 2015 · 2.7K citations · Full text

Pharmacy, Health Informatics, Oncology +17

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer

Mark G. Kris, Ronald B. Natale, Roy S. Herbst et al. · JAMA · 2003 · 2.5K citations

Medicine, Oncology, Pharmacology +17

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers

Helena A. Yu, Maria E. Arcila, Natasha Rekhtman et al. · Clinical Cancer Research · 2013 · 2.5K citations · Full text

Medicine, Oncology, Pharmacology +17